Key market opportunities in oncology biosimilars include leveraging AI for streamlined clinical trials and precision medicine ...
Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...
Credit: Fresenius Kabi. Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion. The biosimilar received FDA approval on ...
The clock of the global pharmaceutical and biotech market is rapidly ticking toward the so-called "patent cliff." As patents ...
Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...
Boehringer Ingelheim has received the Food and Drug Administration’s blessing for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable ...
The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV ...
Celltrion Inc., a major South Korean biopharmaceutical company, said Friday it has launched its biosimilar Avtozma for the ...
With a strong presence in Canada, Australia and New Zealand, Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and ...
RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...